Activation of Fms-Like Tyrosine Kinase 3 Signaling Enhances Survivin Expression in a Mouse Model of Rheumatoid Arthritis

PLoS ONE

Volumn 7, Issue 10, 2012, Pages

  Andersson, Sofia E M ^a   Svensson, Mattias N D ^a   Erlandsson, Malin C ^a   Dehlin, Mats ^a   Andersson, Karin M E ^a   Bokarewa, Maria I ^a  

^a SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

CD135 ANTIGEN; FLT3 LIGAND; GLYCOPROTEIN P 15095; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; METHOTREXATE; SHORT HAIRPIN RNA; SUNITINIB; SURVIVIN;

ADULT; AGED; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BONE MARROW CELL; CELL DIFFERENTIATION; CELL MATURATION; CELL POPULATION; CELL SURVIVAL; CONTROLLED STUDY; DENDRITIC CELL; DISEASE DURATION; ENZYME ACTIVATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; HUMAN; LEUKOCYTE; MAJOR CLINICAL STUDY; MALE; MOUSE; NONHUMAN; PROTEIN EXPRESSION; RHEUMATOID ARTHRITIS; SIGNAL TRANSDUCTION; SPLEEN CELL; UPREGULATION;

ADULT; AGED; AGED, 80 AND OVER; ALTERNATIVE SPLICING; ANIMALS; ARTHRITIS, RHEUMATOID; BONE MARROW; DISEASE MODELS, ANIMAL; DOWN-REGULATION; ENZYME ACTIVATION; FEMALE; FMS-LIKE TYROSINE KINASE 3; HUMANS; INHIBITOR OF APOPTOSIS PROTEINS; MALE; MEMBRANE PROTEINS; MICE; MICE, INBRED BALB C; MIDDLE AGED; REPRESSOR PROTEINS; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; SPLEEN; UP-REGULATION; YOUNG ADULT;

EID: 84867654152     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0047668     Document Type: Article

References (50)

1. Altieri DC, (2010) Survivin and IAP proteins in cell-death mechanisms. Biochem J 430: 199-205.
2. Noton EA, Colnaghi R, Tate S, Starck C, Carvalho A, et al. (2006) Molecular analysis of survivin isoforms: evidence that alternatively spliced variants do not play a role in mitosis. J Biol Chem 281: 1286-1295.
3. Xia F, Altieri DC, (2006) Mitosis-independent survivin gene expression in vivo and regulation by p53. Cancer Res 66: 3392-3395.
4. Aoki Y, Feldman GM, Tosato G, (2003) Inhibition of STAT3 signaling induces apoptosis and decreases survivin expression in primary effusion lymphoma. Blood 101: 1535-1542.
5. Kim PJ, Plescia J, Clevers H, Fearon ER, Altieri DC, (2003) Survivin and molecular pathogenesis of colorectal cancer. Lancet 362: 205-209.
6. Takahashi R, Deveraux Q, Tamm I, Welsh K, Assa-Munt N, et al. (1998) A single BIR domain of XIAP sufficient for inhibiting caspases. J Biol Chem 273: 7787-7790.
7. Jeyaprakash AA, Klein UR, Lindner D, Ebert J, Nigg EA, et al. (2007) Structure of a Survivin-Borealin-INCENP core complex reveals how chromosomal passengers travel together. Cell 131: 271-285.
8. Conway EM, Pollefeyt S, Cornelissen J, DeBaere I, Steiner-Mosonyi M, et al. (2000) Three differentially expressed survivin cDNA variants encode proteins with distinct antiapoptotic functions. Blood 95: 1435-1442.
9. Kang BH, Xia F, Pop R, Dohi T, Socolovsky M, et al. (2011) Developmental Control of Apoptosis by the Immunophilin Aryl Hydrocarbon Receptor-interacting Protein (AIP) Involves Mitochondrial Import of the Survivin Protein. J Biol Chem 286: 16758-16767.
10. Marusawa H, Matsuzawa S, Welsh K, Zou H, Armstrong R, et al. (2003) HBXIP functions as a cofactor of survivin in apoptosis suppression. EMBO J 22: 2729-2740.
11. Leung CG, Xu Y, Mularski B, Liu H, Gurbuxani S, et al. (2007) Requirements for survivin in terminal differentiation of erythroid cells and maintenance of hematopoietic stem and progenitor cells. J Exp Med 204: 1603-1611.
12. Li F, Cheng Q, Ling X, Stablewski A, Tang L, et al. (2010) Generation of a novel transgenic mouse model for bioluminescent monitoring of survivin gene activity in vivo at various pathophysiological processes: survivin expression overlaps with stem cell markers. Am J Pathol 176: 1629-1638.
13. Xing Z, Conway EM, Kang C, Winoto A, (2004) Essential role of survivin, an inhibitor of apoptosis protein, in T cell development, maturation, and homeostasis. J Exp Med 199: 69-80.
14. Okada H, Bakal C, Shahinian A, Elia A, Wakeham A, et al. (2004) Survivin loss in thymocytes triggers p53-mediated growth arrest and p53-independent cell death. J Exp Med 199: 399-410.
15. Song J, So T, Cheng M, Tang X, Croft M, (2005) Sustained survivin expression from OX40 costimulatory signals drives T cell clonal expansion. Immunity 22: 621-631.
16. Kornacker M, Verneris MR, Kornacker B, Scheffold C, Negrin RS, (2001) Survivin expression correlates with apoptosis resistance after lymphocyte activation and is found preferentially in memory T cells. Immunol Lett 76: 169-173.
17. Altznauer F, Martinelli S, Yousefi S, Thurig C, Schmid I, et al. (2004) Inflammation-associated cell cycle-independent block of apoptosis by survivin in terminally differentiated neutrophils. J Exp Med 199: 1343-1354.
18. Fukuda S, Pelus LM, (2001) Regulation of the inhibitor-of-apoptosis family member survivin in normal cord blood and bone marrow CD34(+) cells by hematopoietic growth factors: implication of survivin expression in normal hematopoiesis. Blood 98: 2091-2100.
19. Carter BZ, Milella M, Altieri DC, Andreeff M, (2001) Cytokine-regulated expression of survivin in myeloid leukemia. Blood 97: 2784-2790.
20. Gu L, Chiang KY, Zhu N, Findley HW, Zhou M, (2007) Contribution of STAT3 to the activation of survivin by GM-CSF in CD34+ cell lines. Exp Hematol 35: 957-966.
21. Williams NS, Gaynor RB, Scoggin S, Verma U, Gokaslan T, et al. (2003) Identification and validation of genes involved in the pathogenesis of colorectal cancer using cDNA microarrays and RNA interference. Clin Cancer Res 9: 931-946.
22. Kuttler F, Valnet-Rabier MB, Angonin R, Ferrand C, Deconinck E, et al. (2002) Relationship between expression of genes involved in cell cycle control and apoptosis in diffuse large B cell lymphoma: a preferential survivin-cyclin B link. Leukemia 16: 726-735.
23. Morgillo F, Woo JK, Kim ES, Hong WK, Lee HY, (2006) Heterodimerization of insulin-like growth factor receptor/epidermal growth factor receptor and induction of survivin expression counteract the antitumor action of erlotinib. Cancer Res 66: 10100-10111.
24. Tran J, Master Z, Yu JL, Rak J, Dumont DJ, et al. (2002) A role for survivin in chemoresistance of endothelial cells mediated by VEGF. Proc Natl Acad Sci U S A 99: 4349-4354.
25. Petrarca CR, Brunetto AT, Duval V, Brondani A, Carvalho GP, et al. (2011) Survivin as a predictive biomarker of complete pathologic response to neoadjuvant chemotherapy in patients with stage II and stage III breast cancer. Clin Breast Cancer 11: 129-134.
26. Svensson B, Hafstrom I, Forslind K, Albertsson K, Tarkowski A, et al. (2010) Increased expression of proto-oncogene survivin predicts Joint destruction and persistent disease activity in early rheumatoid arthritis. Ann Med 42: 45-54.
27. Bokarewa M, Lindblad S, Bokarew D, Tarkowski A, (2005) Balance between survivin, a key member of the apoptosis inhibitor family, and its specific antibodies determines erosivity in rheumatoid arthritis. Arthritis Res Ther 7: R349-358.
28. Isgren A, Forslind K, Erlandsson M, Axelsson C, Andersson S, et al. (2012) High survivin levels predict poor clinical response to infliximab treatment in patients with rheumatoid arthritis. Semin Arthritis Rheum 41: 652-657.
29. Ahn JK, Oh JM, Lee J, Bae EK, Ahn KS, et al. (2010) Increased extracellular survivin in the synovial fluid of rheumatoid arthritis patients: fibroblast-like synoviocytes as a potential source of extracellular survivin. Inflammation 33: 381-388.
30. Dharmapatni AA, Smith MD, Findlay DM, Holding CA, Evdokiou A, et al. (2009) Elevated expression of caspase-3 inhibitors, survivin and xIAP correlates with low levels of apoptosis in active rheumatoid synovium. Arthritis Res Ther 11: R13.
31. Smith MD, Weedon H, Papangelis V, Walker J, Roberts-Thomson PJ, et al. (2010) Apoptosis in the rheumatoid arthritis synovial membrane: modulation by disease-modifying anti-rheumatic drug treatment. Rheumatology (Oxford) 49: 862-875.
32. Baran M, Mollers LN, Andersson S, Jonsson IM, Ekwall AK, et al. (2009) Survivin is an essential mediator of arthritis interacting with urokinase signalling. J Cell Mol Med 13: 3797-3808.
33. Mera S, Magnusson M, Tarkowski A, Bokarewa M, (2008) Extracellular survivin up-regulates adhesion molecules on the surface of leukocytes changing their reactivity pattern. J Leukoc Biol 83: 149-155.
34. Boyer SW, Schroeder AV, Smith-Berdan S, Forsberg EC, (2011) All hematopoietic cells develop from hematopoietic stem cells through Flk2/Flt3-positive progenitor cells. Cell Stem Cell 9: 64-73.
35. McKenna HJ, Stocking KL, Miller RE, Brasel K, De Smedt T, et al. (2000) Mice lacking flt3 ligand have deficient hematopoiesis affecting hematopoietic progenitor cells, dendritic cells, and natural killer cells. Blood 95: 3489-3497.
36. Mackarehtschian K, Hardin JD, Moore KA, Boast S, Goff SP, et al. (1995) Targeted disruption of the flk2/flt3 gene leads to deficiencies in primitive hematopoietic progenitors. Immunity 3: 147-161.
37. Bigley V, Haniffa M, Doulatov S, Wang XN, Dickinson R, et al. (2011) The human syndrome of dendritic cell, monocyte, B and NK lymphoid deficiency. J Exp Med 208: 227-234.
38. Small D (2006) FLT3 mutations: biology and treatment. Hematology Am Soc Hematol Educ Program: 178-184.
39. Zhou J, Bi C, Janakakumara JV, Liu SC, Chng WJ, et al. (2009) Enhanced activation of STAT pathways and overexpression of survivin confer resistance to FLT3 inhibitors and could be therapeutic targets in AML. Blood 113: 4052-4062.
40. Fukuda S, Singh P, Moh A, Abe M, Conway EM, et al. (2009) Survivin mediates aberrant hematopoietic progenitor cell proliferation and acute leukemia in mice induced by internal tandem duplication of Flt3. Blood 114: 394-403.
41. Chklovskaia E, Nissen C, Landmann L, Rahner C, Pfister O, et al. (2001) Cell-surface trafficking and release of flt3 ligand from T lymphocytes is induced by common cytokine receptor gamma-chain signaling and inhibited by cyclosporin A. Blood. 97: 1027-1034.
42. Deane KD, O'Donnell CI, Hueber W, Majka DS, Lazar AA, et al. (2010) The number of elevated cytokines and chemokines in preclinical seropositive rheumatoid arthritis predicts time to diagnosis in an age-dependent manner. Arthritis Rheum 62: 3161-3172.
43. Dehlin M, Bokarewa M, Rottapel R, Foster SJ, Magnusson M, et al. (2008) Intra-articular fms-like tyrosine kinase 3 ligand expression is a driving force in induction and progression of arthritis. PLoS One 3: e3633.
44. Dehlin M, Andersson S, Erlandsson M, Brisslert M, Bokarewa M, (2011) Inhibition of fms-like tyrosine kinase 3 alleviates experimental arthritis by reducing formation of dendritic cells and antigen presentation. J Leukoc Biol 90: 811-817.
45. Horiuchi K, Morioka H, Takaishi H, Akiyama H, Blobel CP, et al. (2009) Ectodomain shedding of FLT3 ligand is mediated by TNF-alpha converting enzyme. J Immunol 182: 7408-7414.
46. Tussiwand R, Onai N, Mazzucchelli L, Manz MG, (2005) Inhibition of natural type I IFN-producing and dendritic cell development by a small molecule receptor tyrosine kinase inhibitor with Flt3 affinity. J Immunol 175: 3674-3680.
47. Karsunky H, Merad M, Cozzio A, Weissman IL, Manz MG, (2003) Flt3 ligand regulates dendritic cell development from Flt3+ lymphoid and myeloid-committed progenitors to Flt3+ dendritic cells in vivo. J Exp Med 198: 305-313.
48. Schmid MA, Kingston D, Boddupalli S, Manz MG, (2010) Instructive cytokine signals in dendritic cell lineage commitment. Immunol Rev 234: 32-44.
49. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, et al. (1988) The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 31: 315-324.
50. Rozen S, Skaletsky H, (2000) Primer3 on the WWW for general users and for biologist programmers. Methods Mol Biol 132: 365-386.